AnaptysBio, Inc (ANAB) stock
ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30
$49.24+2.63 (+5.64%)
Close on Oct 19, 2026Market cap $2.28BP/E –Yield –
AnaptysBio operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
AnaptysBio's operating income for the twelve months ending Jun 30, 2026 was $312.93M, up 229.5% year over year. For fiscal 2025 it was $226.90M, up 243.0% from the year before. The highest annual figure on record is $226.90M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $226.90M | +243.0% |
| FY2024 | Dec 31, 2024 | $66.15M | – |
| FY2023 | Dec 31, 2023 | -$164.41M | – |
| FY2022 | Dec 31, 2022 | -$115.15M | – |
| FY2021 | Dec 31, 2021 | -$56.81M | – |
| FY2020 | Dec 31, 2020 | -$23.88M | – |
| FY2019 | Dec 31, 2019 | -$107.43M | – |
| FY2018 | Dec 31, 2018 | -$66.72M | – |
| FY2017 | Dec 31, 2017 | -$28.78M | – |
| FY2016 | Dec 31, 2016 | -$3.03M | – |
| FY2015 | Dec 31, 2015 | -$3.32M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $66.96M | – |
| Q1 FY2026 | Mar 31, 2026 | -$34.64M | – |
| Q4 FY2025 | Dec 31, 2025 | $245.91M | +43.4% |
| Q3 FY2025 | Sep 30, 2025 | $34.70M | – |
| Q2 FY2025 | Jun 30, 2025 | -$26.17M | – |
| Q1 FY2025 | Mar 31, 2025 | -$27.54M | – |
| Q4 FY2024 | Dec 31, 2024 | $171.43M | – |
| Q3 FY2024 | Sep 30, 2024 | -$22.76M | – |
| Q2 FY2024 | Jun 30, 2024 | -$40.32M | – |
| Q1 FY2024 | Mar 31, 2024 | -$42.20M | – |
| Q4 FY2023 | Dec 31, 2023 | -$42.14M | – |
| Q3 FY2023 | Sep 30, 2023 | -$37.73M | – |
| Q2 FY2023 | Jun 30, 2023 | -$40.14M | – |
| Q1 FY2023 | Mar 31, 2023 | -$44.40M | – |
| Q4 FY2022 | Dec 31, 2022 | -$25.97M | – |
| Q3 FY2022 | Sep 30, 2022 | -$29.63M | – |
| Q2 FY2022 | Jun 30, 2022 | -$27.80M | – |
| Q1 FY2022 | Mar 31, 2022 | -$31.75M | – |
| Q4 FY2021 | Dec 31, 2021 | -$31.16M | -193.4% |
| Q3 FY2021 | Sep 30, 2021 | -$6.76M | – |
| Q2 FY2021 | Jun 30, 2021 | -$533.00K | – |
| Q1 FY2021 | Mar 31, 2021 | -$18.36M | – |
| Q4 FY2020 | Dec 31, 2020 | $33.35M | – |
| Q3 FY2020 | Sep 30, 2020 | -$24.34M | – |
| Q2 FY2020 | Jun 30, 2020 | -$22.64M | – |
| Q1 FY2020 | Mar 31, 2020 | -$10.25M | – |
| Q4 FY2019 | Dec 31, 2019 | -$22.26M | – |
| Q3 FY2019 | Sep 30, 2019 | -$33.75M | – |
| Q2 FY2019 | Jun 30, 2019 | -$26.66M | – |
| Q1 FY2019 | Mar 31, 2019 | -$24.77M | – |
| Q4 FY2018 | Dec 31, 2018 | -$19.66M | – |
| Q3 FY2018 | Sep 30, 2018 | -$16.89M | – |
| Q2 FY2018 | Jun 30, 2018 | -$14.42M | – |
| Q1 FY2018 | Mar 31, 2018 | -$15.76M | – |
| Q4 FY2017 | Dec 31, 2017 | -$7.15M | – |
| Q3 FY2017 | Sep 30, 2017 | -$9.09M | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.56M | – |
| Q1 FY2017 | Mar 31, 2017 | -$9.99M | – |
| Q4 FY2016 | Dec 31, 2016 | -$3.17M | – |
| Q3 FY2016 | Sep 30, 2016 | -$1.08M | – |
See a number that looks wrong?